Literature DB >> 22947353

Combined blockade of the renin system: an example of hormesis.

Lawrence R Krakoff1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22947353      PMCID： PMC8108749          DOI： 10.1111/j.1751-7176.2012.00681.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  14 in total

1.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

2.  Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.

Authors:  Alan H Gradman; Roland E Schmieder; Robert L Lins; Juerg Nussberger; Yanntong Chiang; Martin P Bedigian
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

3.  An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Authors:  Frank A Holtkamp; Dick de Zeeuw; Merlin C Thomas; Mark E Cooper; Pieter A de Graeff; Hans J L Hillege; Hans-Henrik Parving; Barry M Brenner; Shahnaz Shahinfar; Hiddo J Lambers Heerspink
Journal:  Kidney Int       Date:  2011-03-30       Impact factor: 10.612

4.  Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2012-02-14       Impact factor: 1.636

Review 5.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

6.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Authors:  Christopher B Granger; John J V McMurray; Salim Yusuf; Peter Held; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Marc A Pfeffer; Karl Swedberg
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

7.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

8.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

9.  Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.

Authors:  John J V McMurray; Bertram Pitt; Roberto Latini; Aldo P Maggioni; Scott D Solomon; Deborah L Keefe; Jessica Ford; Anil Verma; Jim Lewsey
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

10.  A blueberry-enriched diet attenuates nephropathy in a rat model of hypertension via reduction in oxidative stress.

Authors:  Carrie M Elks; Scott D Reed; Nithya Mariappan; Barbara Shukitt-Hale; James A Joseph; Donald K Ingram; Joseph Francis
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.